Burnett will replace Frank Grillo who will stay in his role until November 6 and will continue to serve as an executive advisor afterwards, the Irvine, Calif.-based company said.
“I am thrilled to join the MRI team and help lead this next chapter which will focus on clinical development, market adoption and continued procedure growth. The stakes are high in neurosurgical procedures and precision is paramount. Our team is well positioned by having a real-time navigation solution which we believe will enable the transition to more minimally invasive procedures and ultimately benefit both the patient and the hospital. We have seen that trend in every field in medical devices and each time navigation has been an essential part of the solution. Frank has done an incredible job setting the stage both financially and strategically by building a strong balance sheet and cash position, and by developing a product suitable across a range of growing procedure types. I look forward to continuing that work and ensuring that more patients benefit from these life-altering therapies,” Burnett said in a prepared remarks.
During his career, Burnett has held positions at Guidant and Volcano and acted as VP and GM at Philips, MRI Interventions said.
“I am very pleased with the progress we have made over the last three years as a company and a team. We focused on the neuro navigation opportunity, and made great progress driving the adoption of our ClearPoint System which has resulted in the tripling of product revenue in three years. We have strengthened our balance sheet, which enables further investment in commercialization and the continued development of new therapeutic applications for our intra-operative MRI capabilities. Our foundation and opportunities are stronger than ever before, and I am confident we have found the right person in Joe Burnett to accelerate our growth opportunities,” Grillo said in a prepared statement.
“We are excited to announce Joe Burnett as the new chief executive officer of MRI Interventions. Joe is a strong leader with unique and highly relevant qualifications in the medical device industry and neurology. With his experience and expertise, Joe is ideally suited to lead the company’s next phase of growth, building on the strong foundation established over the last three years under Frank’s leadership. On behalf of the board of directors, we thank Frank Grillo for his leadership, and in particular, for his invaluable contributions to building out our commercialization capabilities and guiding MRI Interventions through the difficult initial phases of market adoption. As Frank transitions, he leaves our company stronger and well positioned for the future. We appreciate his significant efforts over the last three years, and his dedication to the company’s success” board chair Kimble Jenkins said in a press release.
The Paris-based company said that Regnard is already familiar with the company and its technologies as he has previously served as a consultant to the company. In his new position, he will oversee finance, administration, information technology, HR and operations worldwide.
“Since I joined the company, I have been able to fully appreciate the growth potential associated with our unique Cellvizio platform. The progress realized in the past 24 months by the Company on key success factors such as clinical data, regulatory approvals, reimbursement, as well as the strategic choice to move to a consignment business model in the U.S., has uniquely positioned Mauna Kea for success. I am excited to join the executive team at this important stage in the Company’s development,” Regnard said in a press release.
Prior to joining Mauna Kea, Regnard served as deputy CEO and CFO at aeronautics firm Latécoère, the company said.
“Since joining the Company, Olivier has demonstrated strong leadership and has already contributed to the operational and financial improvement of the business. I am very pleased to welcome Olivier as deputy CEO and CFO as we continue to strengthen the Company to execute on our growth strategies,” founder & CEO Sacha Loiseau said in a prepared statement.
Wang currently serves as prez & North Asia managing director and senior VP, leading the company’s business in China, Hong Kong, Taiwan and South Korea. He originally joined the company in 2012 as managing director of China.
“The opportunities and complexities of the Asia Pacific healthcare market offer new inroads and alternatives in the advancement of market appropriate medical technology and access to high quality care. Warren’s experience and keen sense for developing new business collaborations have had a strong influence on our growth in North Asia. We look forward to Warren’s continued leadership in his new role as we pursue our mission of transforming the lives of patients through our innovative medical solutions. I thank Supratim for his many contributions during his distinguished career at Boston Scientific. The AMEA region has grown significantly over the last five years. Supratim’s leadership and commitment to our customers and patients will have lasting impact on Boston Scientific and the medical device industry,” CEO & chair Mike Mahoney said in a press release.
Prior to joining Israel-based Mazor, Hadomi acted as a consultant to Medtronic (NYSE:MDT) ventures and corporate development teams in EMEA and APAC. Before that, he served as COO at Bluewind Medical and co-founder and managing partner of Omega Capital.
“Last year, we began an effort to expand the use of Mazor’s core proprietary technology beyond our current indications to further develop our business with the focus on continued growth and innovation. This effort has progressed to the point where a proven business development leader will move our initiatives forward and maximize our opportunities to heal through innovation. Ron Tavlin brings to Mazor an impressive business development track record. He will lead the implementation of our strategies to develop Mazor’s business beyond our current spine focus as we pursue our goal of being the leader in image based medical robotics,” CEO Ori Hadomi said in a press release.
Boston Scientific said earlier this month that it tapped Desieree Ralls-Morrison as general counsel, corporate secretary and senior VP, effective November 30.
Ralls-Morrison is succeeding current GC and corp secretary Timothy Pratt who announced their retirement in April, the Marlborough, Mass.-based company said.
“Desiree is an accomplished leader in the healthcare industry with deep expertise in broad-ranging legal matters and enterprise business strategy. We look forward to her contributions to Boston Scientific and the company’s continued growth,” chair & CEO Mike Mahoney said in a press release.
Prior to joining Boston Scientific, Ralls-Morrison has served as GC and corp secretary at Boehringer Ingelheim and GC at Johnson & Johnson’s consumer group. She has also served as senior attorney and assistant counsel at Merck.